澳大利亚批准了首次无化疗双向免疫治疗复发性卵泡淋巴瘤. Australia approves first chemo-free dual-targeted immunotherapy for relapsed follicular lymphoma.

澳大利亚已批准MINJUVI (tafasitamab) 与修复剂和莱纳利多米德联合用于复发或耐药的毛囊淋巴瘤患者. Australia has approved MINJUVI (tafasitamab) combined with rituximab and lenalidomide for adults with relapsed or refractory follicular lymphoma. 这标志着该国首个无化疗,双重向免疫治疗方案. This marks the first chemotherapy-free, dual-targeted immunotherapy regimen in the country for this condition. 临床试验显示,该组合改善了无进展生存时间的中位数. Clinical trials showed the combination improved median progression-free survival. 虽然政府正在努力确保公平的医疗接入,但该治疗尚未被政府健康保险计划所覆盖. The treatment is not yet covered by the government’s health insurance scheme, though efforts are underway to ensure equitable access.